As per DelveInsight’s assessment, the Open-Angle Glaucoma Market size in the 7MM was found to be USD 4,500 million in 2021, which is anticipated to grow by 2032. Some of the key factors, such as the increase in the patient pool, improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected entry of emerging therapies, are anticipated to drive the Open-Angle Glaucoma Market growth in the coming years.
There are several unmet needs in the management of Glaucoma, and to meet these unmet needs, various pharmaceutical companies have started working toward developing novel products. Some of the major pharma and biotech giants in the therapeutics market include Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, Nicox Ophthalmics, and others. Over the years, the advances in understanding disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to develop more potential therapeutic targets. Emerging therapies such as DE-117 (omidenepag isopropyl), TC-002, PDP–716 (Brimonidine), DE-130A (latanoprost), Sepetaprost (DE-126/ONO-9054), NCX 470, K-232 (Ripasudil/Brimonidine), and Nyxol (Phentolamine Mesylate, and others have the potential to change the glaucoma treatment landscape. Several of the therapies are in the late and mid-clinical development stages.
DelveInsight’s “Open-Angle Glaucoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Open-Angle Glaucoma market size, share, trends, and growth opportunities in the seven major markets (7MM) [i.e., the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
The Open-Angle Glaucoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Open-Angle Glaucoma: An Overview
Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in the eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment. There are two major types of glaucoma, i.e., Primary open-angle glaucoma (POAG) and Angle-closure glaucoma/closed-angle glaucoma/narrow-angle glaucoma.
Primary open-angle glaucoma is the most common type of glaucoma that happens gradually, where the eye does not drain fluid as well as it should (like a clogged drain). Whereas, angle-closure glaucoma happens when someone’s iris is very close to the drainage angle in their eye.
Open-Angle Glaucoma Market Key Facts
- Total diagnosed prevalence of Glaucoma in 7MM was estimated to be 11,048,000+ in 2021, and the cases are expected to increase during the study period (2019–2032).
- In the EU-5 region, the total diagnosed prevalence of Glaucoma was highest in Germany, with 1,115,000+ cases, followed by Italy, with 965,000+ cases in 2021. Spain reported the least number of cases among EU-5, with 562,000+ cases in 2021.
- Total diagnosed prevalent population of Open-angle Glaucoma (OAG) and Close Angle Glaucoma in the US was estimated to be 3,119,000+ and 347,000+ in 2021.
- The total prevalent population of Glaucoma in Japan was estimated to be 3,388,000+ in 2021 and is expected to decrease during the forecast period (2022–2032).
- According to DelveInsight’s analysis, among the gender-specific prevalent cases, females are affected more by glaucoma than males.
Learn How Open-Angle Glaucoma Market Will Evolve by 2032 @ Open-Angle Glaucoma Therapeutics Market
Open-Angle Glaucoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Open-Angle Glaucoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Open-Angle Glaucoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Open-Angle Glaucoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Open-Angle Glaucoma Epidemiology Segmented by –
- Total Diagnosed Prevalence of Glaucoma in the 7MM (2019-32)
- Gender-specific Diagnosed Prevalence of Glaucoma in the 7MM (2019-32)
- Age-specific Diagnosed Prevalence of Glaucoma in the 7MM (2019-32)
- Type-specific Diagnosed Prevalent Population of Glaucoma (e.g., Open-angle glaucoma, Closed-angle glaucoma) in the 7MM (2019-32)
- Type-specific Diagnosed Prevalence of Open-Angle Glaucoma (e.g., Primary, Secondary) in the 7MM (2019-32)
- Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma (e.g., Steroid-induced, Others) in the 7MM (2019-32)
Open-Angle Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open-Angle Glaucoma market or expected to get launched during the study period. The analysis covers the Open-Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Open-Angle Glaucoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Open-Angle Glaucoma Therapeutics Analysis
Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. To improve the treatment scenario, globally, several key companies are actively working to develop new therapies for the treatment of Open-Angle Glaucoma. Several of the therapies are in the advance of clinical development, anticipated to hit the market in the near future.
As per DelveInsight’s assessment, there are approx. 20+ key companies developing therapies for Open-Angle Glaucoma. Currently, Ocular Therapeutix is leading the therapeutics market with its Open-Angle Glaucoma drug candidates in the most advanced stage of clinical development.
Key Companies in the Open-Angle Glaucoma Therapeutics Market Include:
Aerie Pharmaceuticals, Alcon Research, Allergan, Bausch and Lomb, Chong Kun Dang Pharmaceutical, D.Western Therapeutics Institute (DWTI), Envisia Therapeutics, Kowa LTD., Laboratorios Sophia S.A de C.V., Merck Sharp & Dohme Corp., Nicox Ophthalmics, Novartis, Ocuphire Pharma, Ono Pharmaceutical, Peregrine Ophthalmic, Perrigo Company, Santen Inc., Sun Pharma Advanced Research Company Limited (SPARC), Sylentis, Ube Industries, and many others.
Open-Angle Glaucoma Drugs Covered in the Report Include:
- QLS-101: Qlaris Bio
- Razuprotafib: Aerpio Pharmaceuticals
- NCX-470: Nicox Opthalmics
- Nyxol (Phentolamine Mesylate): Ocuphire Pharma
- Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical
- Bamosiran (SLY040012): Sylentis
- ENV515 (Travoprost XR): Envisia Therapeutics
- POLAT-001: Peregrine Ophthalmic
- TC-002 Latanoprost Ophthalmic solution: TearClear
- Brinzolamide Ophthalmic Solution 1%: Perrigo Company/ Bausch and Lomb
- Ripasudil Hydrochloride Hydrate/Brimonidine tartrate (K-232): Kowa Company/D. Western Therapeutics Institute
- PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)
- And Many More
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF for More Details @ Open-Angle Glaucoma Therapeutics Landscape
Scope of the Open-Angle Glaucoma Market Report:
- Study Period – 2019-2032
- Base Year – 2019
- Geography Covered – 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
- Key Companies Covered – Sylentis, Envisia Therapeutics, Kowa LTD., Laboratorios Sophia S.A de C.V., Merck Sharp & Dohme Corp., Nicox Ophthalmics, Novartis, Ocuphire Pharma, Ono Pharmaceutical, Peregrine Ophthalmic, Ube Industries, Perrigo Company, Aerie Pharmaceuticals, Alcon Research, Allergan, Bausch and Lomb, Chong Kun Dang Pharmaceutical, D.Western Therapeutics Institute (DWTI), Sun Pharma Advanced Research Company Limited (SPARC), Santen Inc., and many others.
- Competitive Intelligence Analysis – SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, Market Entry Strategies
Table of Content
| 1 | Report Introduction |
| 2 | Key Insights |
| 3 | Executive summary |
| 4 | Open-Angle Glaucoma Competitive Intelligence Analysis |
| 5 | Open-Angle Glaucoma Market Overview at a Glance |
| 6 | Open-Angle Glaucoma Disease Background and Overview |
| 7 | Open-Angle Glaucoma Patient Journey |
| 8 | Open-Angle Glaucoma Epidemiology and Patient Population (In the US, EU5, and Japan) |
| 9 | Open-Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices |
| 10 | Open-Angle Glaucoma Unmet Needs |
| 11 | Key Endpoints of Open-Angle Glaucoma Treatment |
| 12 | Open-Angle Glaucoma Marketed Products |
| 13 | Open-Angle Glaucoma Emerging Drugs and Latest Therapeutic Advances |
| 14 | Open-Angle Glaucoma Seven Major Market Analysis |
| 15 | Attribute Analysis |
| 16 | Open-Angle Glaucoma Market Outlook (In US, EU5, and Japan) |
| 17 | Open-Angle Glaucoma Access and Reimbursement Overview |
| 18 | KOL’s Views on the Open-Angle Glaucoma Market |
| 19 | Open-Angle Glaucoma Market Drivers |
| 20 | Open-Angle Glaucoma Market Barriers |
| 21 | Appendix |
| 22 | DelveInsight Capabilities |
| 23 | Disclaimer |
Download Sample PDF to Explore More About the Key Offerings of the Report @ Open-Angle Glaucoma Therapeutics Market Assessment 2032
Related Reports
Open-Angle Glaucoma Epidemiology Forecast
“Open-Angle Glaucoma Epidemiology Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology trends of Open-Angle Glaucoma in the seven major markets (i.e., the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
Open-Angle Glaucoma Pipeline Insight
“Open-Angle Glaucoma Pipeline Insight, 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Open-Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Glaucoma Drainage Devices Market Outlook
The global Glaucoma Drainage Devices Market was valued at USD 640.57 million in 2021, growing at a CAGR of 11.95 % during the forecast period from 2022 to 2027, to reach USD 1,184.39 million by 2027. The increase in demand for glaucoma drainage devices is primarily due to the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development.
“Glaucoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Glaucoma market size, share, trends, and growth analysis in the seven major markets (i.e., the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
Glaucoma Epidemiology Forecast
“Glaucoma Epidemiology Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology trends of Glaucoma in the seven major markets (i.e., the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
“Glaucoma Pipeline Insight, 2023” report provides comprehensive insights into the 70+ companies and 70+ drugs in the Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Primary Open Angle Glaucoma (POAG) Market Outlook
“Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast 2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Open Angle Glaucoma market size, share, trends, and growth analysis in the seven major markets (i.e., the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
Primary Open Angle Glaucoma (POAG) Epidemiology Forecast
“Primary Open Angle Glaucoma (POAG) Epidemiology Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology trends of Primary Open Angle Glaucoma in the seven major markets (i.e., the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom) and Japan.
Primary Open Angle Glaucoma (POAG) Pipeline Insight
“Primary Open Angle Glaucoma (POAG) Pipeline Insight, 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
info@delveinsight.com
+1(919)321-6187